SensiGene Fetal RHD Genotyping
Sequenom Center for Molecular Medicine offers noninvasive prenatal tests that measure circulating cell-free fetal (ccff) nucleic acids from a maternal blood sample.
Now, you can offer a highly-specific direct detection test for fetal RHD status to your patients safely and comfortably from a simple blood sample. The SensiGene™ Fetal RHD Genotyping test is powered by proprietary SEQureDx™ technology, which is based on the pioneering work of Professor Dennis Lo. Through SEQureDx technology, DNA material is extracted from the blood of the mother, enabling direct genetic testing to assess fetal status early in pregnancy.
Reasons to Consider the SensiGene Fetal RHD Genotyping Test
- Aids in the physician management of pregnant RhD negative women.
- Offers direct detection of fetal DNA via simple maternal blood draw.
- Assesses first trimester fetal RHD genotyping status.
- Incorporates a quality control test to facilitate the distinction between maternal and fetal DNA.
- Rigorous validation studies conducted to demonstrate clinical efficacy.
SensiGene Fetal RHD Genotyping Test Performance Data:
| |
|
Confidence Limits
Post Resolution (at 95%) |
| Sensitivity |
97.2% |
92.9% - 98.9% |
| Specificity |
96.9% |
89.5% - 99.2% |
Average gestational age of specimens: 12.5 weeks (range: 11.0-14.1 weeks)
As represented in this graphic, the Sequenom Center for Molecular Medicine believes direct testing of fetal nucleic acids for the RhD blood group has the potential to alter the testing paradigm currently used in medical practice.
|